Please provide your email address to receive an email when new articles are posted on . The FDA has approved bimekizumab-bkzx for three new indications — PsA, AS and non-radiographic axial SpA. The ...
- AbbVie has also submitted results from two studies of upadacitinib in adult patients with ankylosing spondylitis (AS) to request label enhancements in the European Union (EU) - RINVOQ is approved ...
No new safety risks were identified in the studies. Positive topline results were announced from the phase 3 SELECT-AXIS 2 study evaluating upadacitinib in adults with active ankylosing spondylitis ...
BRUSSELS and ATLANTA, Jan. 18, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met ...
The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy. The Food and Drug ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Full 1-year ...
Ankylosing Spondylitis (AS) is the leading chronic progressive inflammatory rheumatic disease that involves the sacroiliac joints (SIJs) and the spinal column but is often difficult to recognize in ...
OAKVILLE, ON, Jan. 15, 2020 /CNW/ - UCB Canada Inc. announced today that Health Canada has approved CIMZIA ® (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial ...
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results